Ikena Oncology Inc - ESG Rating & Company Profile powered by AI
Complete ESG analysis of Ikena Oncology Inc can be accessed by signing in. Other companies in the scoring industry group for Ikena Oncology Inc are displayed below. The assessment of Ikena Oncology Inc is assembled by All Street Sevva using proprietary artificial intelligence.
Ikena Oncology Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.1; made up of an environmental score of 6.0, social score of 1.6 and governance score of 4.8.
4.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 969 | Vertex Pharmaceuticals Inc | 4.2 | High |
| 969 | Zentalis Pharmaceuticals Inc | 4.2 | High |
| 989 | Ikena Oncology Inc | 4.1 | High |
| 989 | Advanz Pharma Corp Ltd | 4.1 | High |
| 989 | Abeona Therapeutics Inc | 4.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Ikena Oncology Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Ikena Oncology Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Ikena Oncology Inc report the average age of the workforce?
Sign up for free to unlockDoes Ikena Oncology Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Ikena Oncology Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Ikena Oncology Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Ikena Oncology Inc offer flexible work?
Sign up for free to unlockDoes Ikena Oncology Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Ikena Oncology Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Ikena Oncology Inc conduct supply chain audits?
Sign up for free to unlockDoes Ikena Oncology Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Ikena Oncology Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Ikena Oncology Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Ikena Oncology Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Ikena Oncology Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Ikena Oncology Inc disclose water use targets?
Sign up for free to unlockDoes Ikena Oncology Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Ikena Oncology Inc have a product recall in the last two years?
Sign up for free to unlockDoes Ikena Oncology Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Ikena Oncology Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Ikena Oncology Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Ikena Oncology Inc disclose parental leave metrics?
Sign up for free to unlockDoes Ikena Oncology Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Ikena Oncology Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Ikena Oncology Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Ikena Oncology Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Ikena Oncology Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Ikena Oncology Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Ikena Oncology Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Ikena Oncology Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Ikena Oncology Inc disclose its waste policy?
Sign up for free to unlockDoes Ikena Oncology Inc report according to TCFD requirements?
Sign up for free to unlockDoes Ikena Oncology Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Ikena Oncology Inc disclose energy use targets?
Sign up for free to unlockDoes Ikena Oncology Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Ikena Oncology Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Ikena Oncology Inc
These potential risks are based on the size, segment and geographies of the company.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.